Alkermes shares take another hit as the FDA shakes its head — again — on a weak case for '5461
The FDA really, really doesn’t like Alkermes’ NDA for its highly touted depression drug ALKS-5461.
Gunned down by agency experts in a lopsided adcomm vote …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
